Cargando…

Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma

INTRODUCTION: Cholangiocarcinoma (CCA) is the second most common type of primary liver cancer. Several factors, such as epigenetic changes in promoter genes, gene expression, and microRNAs (miR), can contribute to genomic instability in cancer. This study aimed at evaluating the expression of VEGF,...

Descripción completa

Detalles Bibliográficos
Autores principales: Calastri, Maria Clara Jessica, Ferreira, Rafael Fernandes, Tenani, Graciele Domitila, Spinola, Lucas Poleto, Vieira, Gabriel Feltrin, Rabaça Roque Botelho, Maria Filomena, Abrantes, Ana Margarida Coelho, Tralhão, José Guilherme Lopes Rodrigues, de Brito, Ana Filipa Marques, da Silva, Renato Ferreira, da Silva, Rita de Cassia Martins Alves, Zanovelo, Eliane Milharcix, da Costa, Larissa Bastos Eloy, Brito de Souza, Danielle Caroline, Neto, Dalisio de Santi, Ferreira Boin, Ilka de Fátima Santana, Souza, Dorotéia Rossi Silva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727337/
https://www.ncbi.nlm.nih.gov/pubmed/35901327
http://dx.doi.org/10.31557/APJCP.2022.23.7.2233
_version_ 1784844993428455424
author Calastri, Maria Clara Jessica
Ferreira, Rafael Fernandes
Tenani, Graciele Domitila
Spinola, Lucas Poleto
Vieira, Gabriel Feltrin
Rabaça Roque Botelho, Maria Filomena
Abrantes, Ana Margarida Coelho
Tralhão, José Guilherme Lopes Rodrigues
de Brito, Ana Filipa Marques
da Silva, Renato Ferreira
da Silva, Rita de Cassia Martins Alves
Zanovelo, Eliane Milharcix
da Costa, Larissa Bastos Eloy
Brito de Souza, Danielle Caroline
Neto, Dalisio de Santi
Ferreira Boin, Ilka de Fátima Santana
Souza, Dorotéia Rossi Silva
author_facet Calastri, Maria Clara Jessica
Ferreira, Rafael Fernandes
Tenani, Graciele Domitila
Spinola, Lucas Poleto
Vieira, Gabriel Feltrin
Rabaça Roque Botelho, Maria Filomena
Abrantes, Ana Margarida Coelho
Tralhão, José Guilherme Lopes Rodrigues
de Brito, Ana Filipa Marques
da Silva, Renato Ferreira
da Silva, Rita de Cassia Martins Alves
Zanovelo, Eliane Milharcix
da Costa, Larissa Bastos Eloy
Brito de Souza, Danielle Caroline
Neto, Dalisio de Santi
Ferreira Boin, Ilka de Fátima Santana
Souza, Dorotéia Rossi Silva
author_sort Calastri, Maria Clara Jessica
collection PubMed
description INTRODUCTION: Cholangiocarcinoma (CCA) is the second most common type of primary liver cancer. Several factors, such as epigenetic changes in promoter genes, gene expression, and microRNAs (miR), can contribute to genomic instability in cancer. This study aimed at evaluating the expression of VEGF, miRs 145-3p, and 101-3p in patients with CCA and their potential as biomarkers for diagnosis and prognosis of CCA. MATERIAL AND METHODS : Sixty two patients were studied. Out of these 62 patients, 41 cases had confirm CCA and 21 cases had hepatopathies complications. The RNA was extracted from a paraffined tissue block, and then the synthesis of cDNA was performed. The analysis of the expression of VEGF, miR-145-3p, and miR-101-3p was carried out by polymerase chain reaction in real time. RESULTS: The findings revealed that miRs 145-3p and 101-3p were under expressed in the case group compared to the control group (0.46; 0.17; P = 0.0001, respectively). VEGF was overexpressed in the case group compared to the control group (11.8; P = 0.0001). An increase in miR-145-3p expression level was observed in patients with perihilar CCA compared to those with distal CCA (0.51 ± 0.41; 0.17 ± 0.13; P = 0.0698). Survival rate analysis showed that 41.9% of patients with intrahepatic CCA and 31.5% of patients with extrahepatic CCA were free from death within 11 months, leading to a significant difference (P> 0.05). CONCLUSION: The underexpression of miRNAs, tumor suppressors, the overexpression of VEGF, smoking, and aging were associated with CCA based on our findings. It seems that the reduced expression of the studies miRNAs and increased expression of VEGF can contribute to a decrease in survival rate of patients with tumor in their intrahepatic bile ducts.
format Online
Article
Text
id pubmed-9727337
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-97273372022-12-09 Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma Calastri, Maria Clara Jessica Ferreira, Rafael Fernandes Tenani, Graciele Domitila Spinola, Lucas Poleto Vieira, Gabriel Feltrin Rabaça Roque Botelho, Maria Filomena Abrantes, Ana Margarida Coelho Tralhão, José Guilherme Lopes Rodrigues de Brito, Ana Filipa Marques da Silva, Renato Ferreira da Silva, Rita de Cassia Martins Alves Zanovelo, Eliane Milharcix da Costa, Larissa Bastos Eloy Brito de Souza, Danielle Caroline Neto, Dalisio de Santi Ferreira Boin, Ilka de Fátima Santana Souza, Dorotéia Rossi Silva Asian Pac J Cancer Prev Research Article INTRODUCTION: Cholangiocarcinoma (CCA) is the second most common type of primary liver cancer. Several factors, such as epigenetic changes in promoter genes, gene expression, and microRNAs (miR), can contribute to genomic instability in cancer. This study aimed at evaluating the expression of VEGF, miRs 145-3p, and 101-3p in patients with CCA and their potential as biomarkers for diagnosis and prognosis of CCA. MATERIAL AND METHODS : Sixty two patients were studied. Out of these 62 patients, 41 cases had confirm CCA and 21 cases had hepatopathies complications. The RNA was extracted from a paraffined tissue block, and then the synthesis of cDNA was performed. The analysis of the expression of VEGF, miR-145-3p, and miR-101-3p was carried out by polymerase chain reaction in real time. RESULTS: The findings revealed that miRs 145-3p and 101-3p were under expressed in the case group compared to the control group (0.46; 0.17; P = 0.0001, respectively). VEGF was overexpressed in the case group compared to the control group (11.8; P = 0.0001). An increase in miR-145-3p expression level was observed in patients with perihilar CCA compared to those with distal CCA (0.51 ± 0.41; 0.17 ± 0.13; P = 0.0698). Survival rate analysis showed that 41.9% of patients with intrahepatic CCA and 31.5% of patients with extrahepatic CCA were free from death within 11 months, leading to a significant difference (P> 0.05). CONCLUSION: The underexpression of miRNAs, tumor suppressors, the overexpression of VEGF, smoking, and aging were associated with CCA based on our findings. It seems that the reduced expression of the studies miRNAs and increased expression of VEGF can contribute to a decrease in survival rate of patients with tumor in their intrahepatic bile ducts. West Asia Organization for Cancer Prevention 2022-07 /pmc/articles/PMC9727337/ /pubmed/35901327 http://dx.doi.org/10.31557/APJCP.2022.23.7.2233 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research Article
Calastri, Maria Clara Jessica
Ferreira, Rafael Fernandes
Tenani, Graciele Domitila
Spinola, Lucas Poleto
Vieira, Gabriel Feltrin
Rabaça Roque Botelho, Maria Filomena
Abrantes, Ana Margarida Coelho
Tralhão, José Guilherme Lopes Rodrigues
de Brito, Ana Filipa Marques
da Silva, Renato Ferreira
da Silva, Rita de Cassia Martins Alves
Zanovelo, Eliane Milharcix
da Costa, Larissa Bastos Eloy
Brito de Souza, Danielle Caroline
Neto, Dalisio de Santi
Ferreira Boin, Ilka de Fátima Santana
Souza, Dorotéia Rossi Silva
Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma
title Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma
title_full Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma
title_fullStr Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma
title_full_unstemmed Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma
title_short Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma
title_sort investigating vegf. mir-145-3p, and mir-101-3p expression in patients with cholangiocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727337/
https://www.ncbi.nlm.nih.gov/pubmed/35901327
http://dx.doi.org/10.31557/APJCP.2022.23.7.2233
work_keys_str_mv AT calastrimariaclarajessica investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT ferreirarafaelfernandes investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT tenanigracieledomitila investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT spinolalucaspoleto investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT vieiragabrielfeltrin investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT rabacaroquebotelhomariafilomena investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT abrantesanamargaridacoelho investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT tralhaojoseguilhermelopesrodrigues investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT debritoanafilipamarques investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT dasilvarenatoferreira investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT dasilvaritadecassiamartinsalves investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT zanoveloelianemilharcix investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT dacostalarissabastoseloy investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT britodesouzadaniellecaroline investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT netodalisiodesanti investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT ferreiraboinilkadefatimasantana investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma
AT souzadoroteiarossisilva investigatingvegfmir1453pandmir1013pexpressioninpatientswithcholangiocarcinoma